HARRISBURG – More than $5.2 million has been recovered as part of a settlement between the Attorney General’s Office and a Japanese company – TAP Pharmaceutical Products, now known as Takeda Pharmaceuticals North America – concerning allegations that the company had artificially inflated drug prices in order to increase sales and profits.
The settlement money is reimbursement for state agencies and government benefit programs that were allegedly forced to pay higher prices for drugs, including $2,360,996 for the Pennsylvania Department of Public Welfare; $1,920,048 for PACE (the Pharmaceutical Assistance Contract for the Elderly, run by the Pennsylvania Department of Aging); and $959,753 for PEBTF (the Pennsylvania Employees Benefit Trust Fund).
This most recent settlement is part of a continuing effort by the Attorney General’s Office to address accusations that numerous companies manipulated a drug pricing benchmark known as Average Wholesale Price (“AWP”). In 2004, lawsuits were filed against 15 major drug companies and their subsidiaries over this scheme, where companies allegedly created a “spread” between actual wholesale prices and the AWP and used that spread as a financial incentive for doctors to prescribe or stock various drugs.
To date, the Attorney General’s Office has secured court rulings or settlements totaling more than $116 million for various state agencies and programs as the result of these drug pricing lawsuits.
In December 2010, New Jersey-based Johnson & Johnson, Inc. was found liable for nearly $52 million in damages and civil penalties for falsely reporting the prices of its drugs, following a five-week trial in Commonwealth Court.
Earlier in 2010 the Attorney General’s Office received a $27.6 million award in a case involving Bristol-Myers Squibb. Settlements have also been reached with a number of other pharmaceutical companies accused of similar price activity, including a $10 million agreement with Astra Zeneca, of Wayne Pa.; $6.95 million from Illinois-based Abbott Laboratories; $1.8 million from GlaxoSmithKline, of Philadelphia; and a $13 million collective settlement with Amgen Inc., of Thousand Oaks, Calif., Baxter Healthcare Corp., of Deerfield, Ill., and Boehringer Ingelheim Roxane of Ridgefield, Conn.
